Clinical Trial: Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07039578) titled 'Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis' on June 18.

Brief Summary: to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: Primary Light-Chain Amyloidosis

Intervention: BIOLOGICAL: CM336 Injection(Low dose group)

subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.

BIOLOGICAL: CM336 Injection(High dose group)

subcutaneous CM336 administration, step-up dosin...